A carregar...
Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline treatment option for metastatic hormone receptor–positive breast cancer. Approximately, 25% to 30% of women may have resistance to endocrine therapy, especially in the setting of certain genomic mutations in the...
Na minha lista:
| Publicado no: | Breast Cancer (Auckl) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7747096/ https://ncbi.nlm.nih.gov/pubmed/33402826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1178223420976387 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|